共 50 条
- [6] Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan [J]. Ophthalmology and Therapy, 2023, 12 : 2005 - 2021
- [7] Correction: Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan [J]. Ophthalmology and Therapy, 2023, 12 : 2821 - 2822
- [8] Pegaptanib for neovascular age-related macular degeneration [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (27): : 2805 - 2816
- [9] Brolucizumab vs aflibercept and ranibizumab for neovascular age-related macular degeneration: a cost-effectiveness analysis [J]. JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2021, 27 (06): : 743 - 752